RecruitingNot ApplicableNCT03905239

A Procalcitonin-based Algorithm in Adhesion-related Small Bowel Obstruction

Impact of a Procalcitonin-based Algorithm on Quality of Management in Patients With Uncomplicated Adhesion-related Small Bowel Obstruction Assessed by Textbook Outcome: a Multicenter Cluster-randomized Open-label Controlled Trial. (ALPROC)


Sponsor

Centre Hospitalier Universitaire, Amiens

Enrollment

488 participants

Start Date

Apr 1, 2019

Study Type

INTERVENTIONAL

Conditions

Summary

Adhesion-related small bowel obstruction is a common digestive emergency that can be managed either conservatively or surgically. However, the choice between these two approaches can be difficult due to the absence of specific signs. The objective of this study is to evaluate the clinical impact of a procalcitonin-based algorithm.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Uncomplicated acute adhesion-related small bowel obstruction (ASBO)
  • Adults
  • Patients able to express consent
  • Signed written informed consent form
  • Covered by national health insurance

Exclusion Criteria13

  • Disease-related criteria:
  • Large bowel obstruction
  • No previous abdominal surgery
  • Signs of peritonitis or strangulation requiring emergency surgery)
  • Obstruction within 4 weeks following previous surgery
  • Ongoing or history of bowel cancer
  • Ongoing or in history of inflammatory bowel disease
  • History of abdominal radiotherapy
  • Active infection
  • Contraindication to contrast-enhanced CT scan
  • Minors
  • Patient deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision)
  • Pregnancy or breastfeeding

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTalgorithm

clinical examination and procalcitonin assessment


Locations(1)

Amiens Universitary Hospital

Amiens, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03905239


Related Trials